The Asia-Pacific (APAC) Alzheimer’s Disease (AD) market is forecast to grow from $3 billion in 2014 to $5.1 billion in 2021 at a CAGR of 7.9%. Over the forecast period the prevalence of AD and Mild Cognitive Impairment (MCI) is expected to increase across the APAC markets, mainly due to an aging population, as the disease is more common among the elderly. The rising prevalence population, together with better diagnostic techniques, improving health awareness, special healthcare programs for elderly populations, health insurance coverage and increasing affordability, especially in India and China, will increase diagnosis and the treatment-receiving population, driving demand and contributing to market growth. However, incidence of AD and MCI is notably lower in Asia than in western countries. AD is more common in industrialized, western countries than in Asia. The incidence of AD and MCI is low in Asia due to a lower life expectancy than in western countries. Moreover, people who live in Asia have protective factors against AD which have not been explored completely, leading to the disease being less prevalent in these countries.
GBI Research’s Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies report provides analysis of the Alzheimer’s disease treatment space across the Asia-Pacific countries of India, China, Australia and Japan, with annualized market date from 2014 and forecast to 2021. It includes analysis of the Alzheimer’s disease pipeline stratified by stage of development, molecule type, and molecular target.
Single User Price: $4,995